Screener
Twist Bioscience Corporation TWST Reportable Segment — Restructuring and other costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Twist Bioscience Corporation in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCosts.
The source filing: Twist Bioscience Corporation’s 10-K, filed November 17, 2025.
- Filed
- Nov 17, 2025
- Fiscal year
- FY2025
- Accession
- 0001581280-25-000025
| (In thousands) | Year ended September 30, 2025 | Year ended September 30, 2024 | Year ended September 30, 2023 |
|---|---|---|---|
| Selling, general and administrative expenses[1] | 192,024 | 175,883 | 171,070 |
| Depreciation and amortization | 24,853 | 31,432 | 29,310 |
| Stock-based compensation expense | 64,459 | 50,925 | 30,278 |
| Restructuring and other costs | — | — | 9,384 |
| Change in fair value of contingent considerations and holdbacks | — | — | (5,913) |
| Impairment of long-lived assets | — | 44,930 | 6,785 |
| Total costs and expenses | $512,831 | $533,805 | $462,268 |
| Loss from operations | $(136,259) | $(220,831) | $(217,159) |
Item 8. tatements and
FAQ
- What is Twist Bioscience Corporation's reportable segment — restructuring and other costs?
- Twist Bioscience Corporation (TWST) reported reportable segment — restructuring and other costs of $0 in Q3 2025.
- What is the long-term trend for Twist Bioscience Corporation's reportable segment — restructuring and other costs?
- Over 2 years (2023 to 2025), Twist Bioscience Corporation's reportable segment — restructuring and other costs has grown at a -100.0% compound annual growth rate (CAGR), from $9.38M to $0.
- What does reportable segment — restructuring and other costs mean?
- This metric captures non-recurring expenses associated with organizational changes, such as workforce reductions, facility consolidations, or strategic realignments within the reportable segment. These costs are typically excluded from core operating performance analysis to better understand the underlying business trends. High levels of these costs may indicate significant operational shifts or management efforts to improve long-term efficiency.
Ask your AI about Twist Bioscience Corporation's reportable segment — restructuring and other costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude